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Abstract
Background: The purpose of this study was to evaluate the role of osteoprotegerin gene (OPG)
polymorphisms as genetic modifiers in the etiology of prostate cancer (PCa) and disease
progression.
Methods: Three hundred and sixty one patients with PCa and 195 normal controls were enrolled
in the study, and two genetic polymorphisms, 149 T/C and 950 T/C in the putative promoter region
of OPG, were genotyped.
Results: There was no significant difference in the genotype frequencies between PCa patients and
controls (P = 0.939 and 0.294 for 149 T/C and 950 T/C polymorphisms, respectively). However,
those patients with TC and TT genotypes in the 950 T/C polymorphism had a significantly increased
risk of extraprostatic (age-adjusted odds ratio; aOR = 1.74 and 2.03 for TC and TT genotypes
compared with the CC genotype, P = 0.028) and metastatic disease (aOR = 1.72 and 2.76 for TC
and TT genotypes compared with the CC genotype, P = 0.009) compared with those with the CC
genotype. In addition, analysis of the metastatic PCa patients (Stage D) showed that the presence
of the T allele of the OPG 950 T/C polymorphism was an independent risk factor predicting survival
by Cox proportional hazard regression analyses (P = 0.031).
Conclusion: Progression of PCa may be influenced by an intrinsic genetic factor of the host's bone
metabolism. The variant C allele of 950 T/C in the OPG promoter may play a major role as a genetic
safe guard against progression in patients with PCa.
Background
Prostate cancer (PCa) has a very high proclivity for metas-
tasizing to bone, with approximately 90% of men with
advanced disease having skeletal lesions [1]. Bone is an
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abundant repository for immobilized growth factors.
When osteoclasts absorb bone by secreting protons and
proteases, these growth factors are released and provide
fertile ground in which tumor cells can grow. Bone-
derived growth factors and adhesive molecules secreted by
tumor cells can cause modifications in the development
and progression of metastatic cancer growth. Indeed, our
recent investigation disclosed that a genetic polymor-
phism in the insulin-like growth factor I gene (IGF1) is a
strong modifier of PCa progression [2]. Thus, genetic fac-
tors involved in the interaction between prostate cancer
cells and normal host cells in the bone environment such
as osteoclasts and osteoblasts may be a significant deter-
minant in the progression, and bone metastasis, of pros-
tate cancer.
The receptor activator of nuclear factor-kappa B (RANK,
also called tumor necrosis factor receptor super family
member 11A; TNFRSF11A), its ligand, RANKL (also called
TNF ligand super family member 11; TNFSF11), and oste-
oprotegerin (OPG, also called as TNFRSF11B) are the
major regulators of bone metabolism [3,4]. RANKL is a
cytokine produced by osteoblasts that stimulates osteo-
clast activity and inhibits osteoclast apoptosis through
binding to its receptor, RANK, which is expressed on oste-
oclasts and their precursors [3]. OPG, which acts as an
inhibitor of osteoclastogenesis by serving as a decoy
receptor for RANKL, is a potent inhibitor of osteoclastic
bone resorption and has been investigated as a potential
therapeutic modality for the treatment of both osteoporo-
sis and tumour-induced bone disease [3-6].
The promoter region of human OPG  contains various
putative transcription factor binding sites that may medi-
ate the stimulation of OPG expression by different calcio-
tropic factors [7]. Polymorphisms in this region of OPG
may contribute to the genetic regulation of bone mass, as
suggested by several recent publications [8-13]. Through
the inhibition of osteoclast-genesis, OPG has been sug-
gested to be an important modifier of bone metabolism
and bone metastasis [3-6]. Consequently, in this study we
used a cohort of 361 PCa patients and 195 male controls
to investigate the hypothesis that polymorphisms in the
promoter region of OPG may be genetic modifiers of the
development and progression of PCa.
Methods
Subjects
A total of 556 native Japanese subjects consisting of 361
PCa patients and 195 male controls were enrolled in our
study. Control subjects were selected randomly from a
native Japanese population attending a medical check-up
at our community hospitals in Akita prefecture. All of the
patients with PCa were treated at the Akita University
Medical Center and the Kyoto University Hospital from
January 1991 to January 2006. All of the PCa patients
were diagnosed histologically with specimens obtained
from transrectal needle biopsy or transurethral resection
of the prostate for voiding symptoms. The prostate spe-
cific antigen (PSA) levels of all the controls were measured
and men with a PSA level of 4.0 ng/ml or more were omit-
ted from the control group. The pathological grading and
clinical stage of PCa were determined according to the
Tumor-Node-Metastatic system, the Gleason's histologi-
cal grading, and the modified Whitmore-Jewett system
[14-16]. All pathological grading was based on needle
biopsy specimens in stage B-D patients and surgical spec-
imens in stage A patients. We categorized the tumor grad-
ing into 3 groups: a high grade group consisting of
Gleason 8–10 or poorly differentiated adenocarcinoma,
an intermediate grade group consisting of Gleason 5–7 or
moderately differentiated adenocarcinoma and a low
grade group consisting of Gleason 2–4 or well-differenti-
ated adenocarcinoma [2]. The study was carried out in
compliance with the Helsinki declaration and was
approved by the institutional review board at Akita Uni-
versity School of Medicine. Written informed consent was
obtained from all of the subjects in this study.
OPG genotyping analysis
OPG  genotyping was analyzed by a polymerase chain
reaction restriction fragment length polymorphism (PCR-
RFLP) method. Two DNA fragments spanning 178 bp
containing the 149 T/C single nucleotide polymorphism
(SNP, rs3134071, 1024 bp upstream of the translation
initiation site) and 147 bp containing the 950 T/C SNP
(rs2073617, 223 bp upstream of the translation initiation
site) in the OPG 5' untranslated region were amplified




3' for the fragment containing the 149 T/C and 950 T/C
SNPs, respectively. Each PCR reaction was performed as
described previously [2]. Digestion of the fragment con-
taining 149 T/C with XbaI resulted in two fragments of
129 and 49 bp containing the C allele, and a 178 bp frag-
ment containing the T allele. On the other hand, digestion
of the PCR products containing 950 T/C by HincII resulted
in 2 fragments of 110 and 37 bp with the C allele, and a
147 bp fragment with the T allele. These genotypes were
confirmed by an automated sequencer (ABI PRISM 310
Genetic Analyzer; GMI Inc, Ramsey, MN) with GENES-
CAN software (Applied Biosystems, Foster City, CA).
Determination of the serum level of OPG
The serum levels of OPG in 192 male controls and 66 PCa
patients were determined using enzyme-linked immuno-
sorbent assays (ELISA, R&D Systems, Minneapolis, MN)
according to the manufacturer's protocol. This controlBMC Cancer 2008, 8:224 http://www.biomedcentral.com/1471-2407/8/224
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group consisted of 192 healthy volunteers, who were
recruited in Akita prefecture and whose serum PSA levels
were less than 4.0 ng/dl.
Statistical Analysis
Hardy-Weinberg equilibrium analyses were performed to
compare the observed genotype frequencies of each cate-
gory with the expected ones using a chi-square test
(degrees of freedom = 1). The frequency of each allele and
the relationship between each genotype were analyzed by
chi-square analysis. Possible significant differences in age
and serum variables in each genotype-stratified group
were assessed by two-way analysis of variance (ANOVA).
The age-adjusted odds ratio (aOR) and 95% confidence
interval (CI) for the relative risk of PCa and the relation-
ship between the genotype distribution and the tumor
grade or stage were determined by multivariate logistic
regression analysis with the inclusion of the factor of age.
In addition, the gene dosage effect of the T  allele was
assessed by modeling a linear effect on the log odds scale
for each T allele in a multivariate logistic regression, for
example the genotypes TT, TC, and CC were assigned the
values "2," "1," and "0," respectively. Survival time was
calculated from the date of prostate cancer diagnosis to
the day of cancer-specific death, with deaths from other
causes excluded. Cancer-specific survival was estimated
using the Kaplan-Meier method and the differences in sur-
vival were tested using the log rank test. Hazard ratios
(HRs) and 95% CIs for cancer death were assessed by the
Cox proportional hazard regression model. All of the data
were entered into an access database and analyzed using
the Excel 2000 and SPSS (version 10.0J; SPSS, Inc.) soft-
ware. A probability (P) of < 0.05 was considered to be sta-
tistically significant. The linkage disequilibrium between
the two loci was analyzed with LDA software (Linkage
Disequilibrium Analyzer, version 1.0, Chinese National
Human Genome Center, Beijing, China).
Results
Subject Characteristics
The mean age ± SD was 64.6 ± 9.2 years for the controls
and 66.8 ± 10.0 for the PCa patients. The controls were
significantly younger than the PCa patients (P = 0.042).
There were 24 stage A patients whose PCa was diagnosed
incidentally by specimens removed for Benign prostatic
hyperplasia (BPH) treatment. By clinical findings, 184
and 56 patients with PCa were classified into stage B and
C disease, respectively. In total, 97 patients were classified
as having metastatic PCa; eleven PCa patients had clinical
stage D1 disease, while 86 had clinical D2 disease judged
by radiological studies. (Table 1).
OPG genotypes and risk of PCa
A recent report revealed that the OPG polymorphisms in
the promoter region, 149 T/C, 209 G/A, and 245 T/G are
in strong linkage disequilibrium [9]. These three polymor-
phisms have been shown to provide TGT or CAG haplo-
types [9]; therefore we investigated the genotype of 149 T/
C among these polymorphisms. In addition, we analyzed
another polymorphism, 950 T/C, which is located 801 bp
downstream of the 149 T/C polymorphism. There is no
report showing any linkage disequilibrium between the
polymorphism at 950 T/C and any other surrounding
SNPs. We examined the linkage disequilibrium between
these two loci. The r2 and D' value of the patients with PCa
were 0.1163 and 0.6875, respectively. These results sug-
gested that no tight linkage disequilibrium between the
two loci was shown. The frequencies of the 149 T/C and
950 T/C genotypes in the PCa and control groups are
shown in Table 1. The OPG genotype frequency in each
group (PCa and control) was in Hardy-Weinberg equilib-
rium (P > 0.05, data not shown). No significant differ-
ences in the allele frequencies were found when the PCa
patients (149 T/C; T:C = 0.87:0.13, 950 T/C; T:C =
0.60:0.40) were compared with the controls (149 T/C; T:C
= 0.89:0.11, 950 T/C; T:C = 0.60:0.40). To evaluate the risk
of PCa according to the OPG genotype, logistic regression
analysis was conducted with an adjustment for age at the
time of diagnosis (Table 1). No significant increased risk
was observed among the different genotypes of patients
with PCa and the controls (P = 0.939 and 0.294 for 149 T/
C and 950 T/C polymorphisms, respectively).
OPG Genotypes and PCa disease status
Next, we examined the association between the genotypes
of OPG 149 T/C and 950 T/C and clinicopathological var-
iables at the time of diagnosis. Regarding the 149 T/C pol-
ymorphism, no significant differences in the allele
frequencies were found between low/intermediate and
high grades or between low and high stages (data not
shown).
Regarding the 950 T/C polymorphism, no significant dif-
ferences in the allele frequencies were found between the
low/intermediate and high grades (Table 1). However, the
frequency of the CC genotype in the 950T/C polymor-
phism decreased as the tumor stage increased (Table 1).
The TT and TC genotypes were more frequently observed
in patients with tumors of a higher stage than those of a
lower stage (Table 1). A significant difference in the fre-
quency of the C allele was found between the organ-con-
fined PCa patients (stage A and B; T:C = 0.57:0.43) and
the extraprostatic PCa patients (stage C and D; T:C =
0.65:0.35,  P  = 0.021), and between the localized PCa
patients (stage A, B, and C; T:C = 0.57:0.43) and meta-
static PCa patients (stage D; T:C = 0.69:0.31, P = 0.005)
(Table 1). PCa patients with the TT genotype had a 2.76-
fold and 2.03-fold increased risk of metastatic and extrap-
rostatic diseases, respectively, compared to patients with
the CC genotype (Table 2). When the TT, TC, and CC gen-BMC Cancer 2008, 8:224 http://www.biomedcentral.com/1471-2407/8/224
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otypes were assigned the values "2," "1," and "0", respec-
tively, the presence of the T allele significantly increased
the risk of metastatic disease (aOR = 1.65, 95%CI = 1.17–
2.33, P = 0.005) and extra prostatic disease (aOR = 1.37,
95%CI = 1.01–1.84, P = 0.04) with a gene-dosage effect.
However, no significant difference in the genotype fre-
quency was found among the three subgroups of tumor
grade (low, intermediate, and high grade; P = 0.253).
Patient prognosis with metastatic PCa (Stage D) and OPG 
genotypes
Next, we investigated the association between the clinical
variables and OPG 149 T/C and the 950 T/C genotype in
patients with metastatic PCa (Stage D) after the initial
diagnosis. Among the patients with metastatic PCa, the
outcome and the serum variables of 90 patients were
available for this study. Regarding the 149 T/C polymor-
phism, no significant differences in the allele frequencies
were found between the clinical variables of these patients
Table 1: Osteoprotegerin genotype frequencies in prostate cancer patients (PCa) and control males
149 T/C
149 T/C Genotype C allele frequency (%)
Study group Total no. CC TC TT
PCaa 361 4 (1.1) 84 (23.3) 273 (75.6) 12.742
Stageb
A 24 1 (4.2) 5 (20.8) 18 (75.0) 14.583
B 184 1 (0.5) 40 (21.7) 143 (77.8) 11.413
C 56 1 (1.8) 16 (28.6) 39 (69.6) 16.071
D 97 1 (1.0) 23 (23.7) 73 (75.3) 12.886
Organ confined PCa 208 2 (1.0) 45 (21.6) 161 (77.4) 11.778
Extraprostatic PCa 153 2 (1.3) 39 (25.5) 112 (73.2) 14.052
Localized Pca 264 3 (1.1) 61 (23.1) 200 (75.8) 12.689
Metastatic Pca 97 1 (1.0) 23 (23.7) 73 (75.3) 12.887
Gradec
Low/Intermediate 257 1 (0.4) 55 (21.4) 201 (78.2) 11.089
High 104 3 (2.9) 29 (27.9) 72 (69.2) 16.826
Control 195 3 (1.5) 37 (19.0) 155 (79.5) 11.026
950 T/C
950 T/C Genotype (%) C allele frequency (%)
Study group Total no. CC TC TT
PCaa 361 63 (17.4) 162 (44.9) 136 (37.7) 39.889
Stageb
A 24 8 (33.3) 8 (33.3) 8 (33.3) 50
B 184 36 (19.6) 84 (45.6) 64 (34.8) 42.391
C 56 9 (16.0) 30 (53.6) 17 (30.4) 42.857
D 97 11 (10.3) 39 (41.2) 47 (48.5) 30.927
Organ confined PCa 208 44 (21.2) 92 (44.2) 72 (34.6) 43.269
Extraprostatic PCa 153 19 (12.4) 70 (45.8) 64 (41.8) 35.294
Localized Pca 264 53 (20.0) 122 (46.3) 89 (33.7) 43.181
Metastatic Pca 97 11 (10.4) 39 (41.2) 47 (48.4) 30.927
Gradec
Low/Intermediate 257 48 (18.7) 116 (45.1) 93 (36.2) 41.245
High 104 15 (14.4) 46 (44.3) 43 (41.3) 36.538
Control 195 29 (14.9) 98 (50.2) 68 (34.9) 40
a Prostate cancer versus control, P = 0.939 and 0.294 by the chi-square test for 149 T/C and 950 T/C, respectively.
b According to the Whitmore-Jewett system. Stage A = T1a-bN0M0, Stage B = T1c-2N0M0, Stage C = T3–4N0M0 and Stage D = T1–4N1M0–1 or T1–4N0–
1M1. Localized PCa (Stage A + B + C) versus Metastatic PCa (Stage D) P = 0.931 and 0.005 by the chi-square test for 149 T/C and 950T/C, 
respectively. Organ confined (Stage A + B) versus Extraprostatic PCa (Stage C + D), P = 0.346 and 0.021 by the chi-square test for 149 T/C and 
950T/C, respectively.
c Low grade = well-differentiated carcinoma (WHO) or Gleason score 2–4 carcinoma, Intermediate grade = moderately differentiated carcinoma 
(WHO) or Gleason score 5–7 carcinoma, High grade = poorly differentiated carcinoma (WHO) or Gleason score 8–10 carcinoma. C allele 
frequency, P = 0.884 and 0.520 by the chi-square test for 149 T/C and 950 T/C, respectively.BMC Cancer 2008, 8:224 http://www.biomedcentral.com/1471-2407/8/224
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and the genotype (data not shown). Regarding the 950 T/
C polymorphism, age, initial PSA, hemoglobin, alkaline
phosphatase (ALP), and the biopsy histological grade
were not significantly different among the CC, TC, and TT
genotypes (Table 3). However, although the difference
was not significant, the cause-specific survival of patients
with the CC genotype was better than that of patients with
the TC or TT genotype (OR = 2.938 and 3.018 for TC and
TT genotypes compared with the CC genotype, P = 0.087
and 0.082, respectively. Figure 1). In addition, according
to the multivariate Cox proportional hazard regression
analyses, the T allele of the OPG 950 T/C polymorphism
was an independent risk factor predicting survival with
HRs of 2.157 (95% CI = 1.072 – 4.341, P = 0.031, Table
4) compared to the C allele. These results also suggested
that the variant C allele of 950 T/C in the OPG promoter
may have some protective effect against the progression of
PCa.
Serum level and genotypes of OPG in healthy controls and 
patients with PCa
We hypothesized that the promoter activity of OPG would
reflect the OPG serum level. Consequently, we investi-
gated the association between the serum level of OPG and
149 T/C and 950 T/C genotypes in 192 normal controls
and 74 PCa patients whose serum was available for this
study. The mean serum levels of OPG for all of the normal
controls, the patients with localized PCa and those with
metastatic PCa were 52.6 ± 19.7 pg/ml (n = 192; median
48.7, quartile 39.3–60.4), 84.2 ± 32.7 pg/ml (n  = 66;
median 82.1, quartile 64.4–101), and 122.2 ± 34.4 pg/ml
(n = 8; median 132, quartile 105–141.7), respectively. The
serum level of OPG in patients with PCa was significantly
higher than that of healthy controls (P = 3.50 × 10-22);
however, the age of the patients with PCa was also signif-
icantly higher than that of the healthy controls (P = 1.47
× 10-13). Comparison of the OPG serum level in healthy
controls and patients with PCa was therefore not conclu-
sive. We also investigated the relationship between the
OPG serum level and the 149 T/C and the 950 T/C geno-
types in healthy controls and patients with PCa; no signif-
icant association was found (Figure 2A).
Table 2: Age-adjusted odds ratios according to the Osteoprotegerin950 T/C genotype
Age-adjusted odds ratio (95% CI, P) according to the Osteoprotegerin 950 T/C genotypea
Study group CC TC TT
Prostate cancer against control 1.00 0.60 (0.345–1.032,0.065) 0.73 (0.418–1.302,0.294)
Tumor stageb
Stage D against Stage A+B+C 1.00 1.72 (0.801–3.698, 0.164) 2.76 (1.289–5.938, 0.009)
Stage C+D against Stage A+B 1.00 1.74 (0.937–3.253, 0.079) 2.03 (1.078–3.843, 0.028)
Tumor gradeb
High against Low +Intermediate 1.00 1.27 (0.649–2.498, 0.482) 1.48 (0.750–2.947, 0.256)
a These data were adjusted for age.
b The tumor stage and grade systems are the same as those in Table 1.
Table 3: Association between the clinical variables of patients with metastatic prostate cancer (Stage D) and the OPG 950T/C 
genotype
Osteoprotegerin 950T/C genotype
CC TC TT P3
n = 11 n = 39 n = 40
Age1 74 (69–79) 75 (68–81) 72 (65–76) 0.375
Histological grade2
Low/Intermediate 4 (9%) 18 (39%) 24 (52%) 0.641
High 7 (16%) 21 (48%) 16 (36%)
Clinical variables at diagnosis1
PSA (ng/ml) 199 (66.4–296) 257 (37.3–860) 116 (30.0–267) 0.270
Hemoglobin (g/dl) 12.8 (12.2–13.1) 12.7 (11.1–13.7) 13.2 (12.0–14.6) 0.194
ALP (IU/ml) 189 (175–468) 232 (177–360) 201 (138–343) 0.659
1Values represent the median (inter-quartile range).
2Values represent the number (%).
3Analysis of variance or chi-square test.
Abbreviations: PSA; prostate specific antigen, ALP, alkaline phosphatase.BMC Cancer 2008, 8:224 http://www.biomedcentral.com/1471-2407/8/224
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OPG serum level by age and disease status in healthy 
controls and patients with PCa
We investigated the association between the OPG serum
level and the age and disease status of the healthy controls
and patients with PCa. We detected a significant increase
in the serum levels of OPG with age in the healthy con-
trols, as well as in patients with non-metastatic PCa (stage
B and C, Figure 2B). In addition, there was no significant
Table 4: Multivariate Cox proportional hazard regression analysis of predicting factors for cancer-specific survival of metastatic 
prostate cancer patients (Stage D)
HR Cancer Specific Survival 95% CI P
PSA (ng/ml)
≥260 1.984 0.756–5.210 0.164
< 260
hemoglobin (g/dl)
Abnormal (< 11.7) 2.632 1.140–6.077 0.023
Normal (≥11.7)
ALP (IU)
Abnormal (≥ 282) 2.557 0.994–6.574 0.051
Normal (< 282)
Grade
High 3.251 1.473–7.175 0.004
Low/Intermediate
OPG
T allele dosage 2.157 1.072–4.341 0.031
Abbreviations: HR; hazard ratio, 95% CI; 95% confidence interval, PSA; prostate specific antigen, ALP, alkaline phosphatase, OPG; osteoprotegerin 950 
T/C genotype
Comparison of the outcome of patients with PCa and the 950 T/C OPG genotype Figure 1
Comparison of the outcome of patients with PCa and the 950 T/C OPG genotype. The differences in cause-specific 
survival of the patients with the CC genotype versus the TC and TT genotypes were an OR of 2.938 and 3.018 (P = 0.087 and 
0.082, respectively).BMC Cancer 2008, 8:224 http://www.biomedcentral.com/1471-2407/8/224
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difference between the age-matched serum OPG levels of
the healthy controls and patients with non-metastatic
PCa. The serum level of OPG in age-matched patients
with metastatic PCa (stage D2) was significantly higher
than that of patients without metastatic disease and
healthy controls (P = 0.012 and 0.005, respectively. Figure
2). These results suggest that aging and bone metastasis
have a major effect on the serum level of OPG rather than
PCa.
The serum OPG levels in healthy controls and patients with PCa Figure 2
The serum OPG levels in healthy controls and patients with PCa. (A) Comparison of the serum OPG levels and the 
950 T/C genotype in 192 healthy controls and 66 localized PCa patients. (B) Comparison of the serum OPG level by age and 
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Discussion and conclusion
Over a hundred years ago, Stephen Paget enunciated the
"seed and soil" hypothesis in which seeds of metastatic
cancer cells preferentially settle in the soil of the bone
matrix, where there is an abundant repository for immo-
bilized growth factor [17]. In this study, we hypothesized
that the host's bone metabolism may modify disease
development and progression. Among many factors that
play important roles in bone metabolism, OPG is a major
factor in osteoclastgenesis and is known as osteoclast
inhibitory factor [3,4]. In this study, no significant differ-
ences in the allele frequencies of 149 T/C polymorphism
were found in the clinical and pathological variables in
the patients with PCa. However, this study demonstrated
that the C allele of the 950 T/C polymorphism in the OPG
promoter region decreased the risk of advanced PCa with
a gene-dosage effect. The C allele was found at a signifi-
cantly lower frequency in patients with metastatic (stage
D) and extraprostatic PCa (stage C+D) than in patients
with localized (stage A+B+C) and organ confined PCa
(stage A+B) (Table 2). In addition, the analysis of meta-
static PCa patients (Stage D) revealed that the T allele of
the OPG 950 T/C polymorphism was an independent risk
factor predicting survival compared to the C allele by Cox
proportional hazard regression analyses (P  = 0.031).
Although the 950 T/C is not a putative transcription factor
binding site, an altered secondary structure may cause dif-
ferences in OPG  mRNA expression. Therefore, these
results suggest that the T/C allele of the 950 T/C polymor-
phism functions as a modifier of OPG expression and has
some effect on metastasis and the spread of PCa cells.
Alternatively, it is possible that this polymorphism is in
linkage disequilibrium with other SNP(s) that alters OPG
function.
Although conflicting results have been documented [8-
10], the genotype of the 950 T/C polymorphism has been
reported to be independently associated with a subset of
osteoporosis or bone marrow density (BMD). Vidal et al.
reported that the T allele of the 950 T/C polymorphism
was associated with low BMD, although statistical signifi-
cance was not reached [11]. Arko et al. also revealed that
the homozygote CC genotype of the 950 T/C polymor-
phism had the highest BMD of all of the anatomical sites
[12]. In addition, Ohmori et al. demonstrated that the TT
genotype had a significantly lower BMD than the TC and
CC genotypes by parametric and non parametric analysis
[13]. Interestingly, they used healthy DNA samples from
the same prefecture, Akita in Japan. In addition, recent
studies reported that the C allele 950 T/C polymorphism
contributed to calcification of the vascular system and the
osseous tissue [18-20].
Instead of measuring the expression level of OPG in the
bone tissues, we compared the serum level of OPG for
each of the genotypes; however, there was no difference
among these genotypes either in the healthy controls or
the patients with PCa. The serum level of OPG was signif-
icantly higher in patients with bone metastasis than those
without bone metastasis; this is in agreement with previ-
ous reports [21-23]. In addition, we found that the serum
level of OPG in the older individuals was significantly
higher than that of the younger ones. Our results support
previous findings that the serum levels of OPG increase
with age in relatively large healthy adult Caucasian popu-
lations [24,25]. In contrast, Lipton et al. reported that
serum OPG values did not differ significantly by age,
although they analyzed male and female healthy control
samples together [26]. The relationship between age and
serum OPG warrants further investigation because
healthy controls have a tendency to be younger than
patients with cancer, and patients with advanced stage dis-
ease are usually older than those with early stage cancer.
Cao et al. demonstrated that OPG mRNA levels in bones
of the adult male mouse were lower than those in young
mice [27]. These results indicate that the serum levels of
OPG do not precisely reflect the expression profile or OPG
level in the local bone environment. Therefore, we could
not confirm whether each 950 T/C polymorphism geno-
type had a considerable effect on OPG expression.
In conclusion, the OPG 950 T/C polymorphism was not
associated with susceptibility to PCa in Japanese men.
However, the presence of the variant C allele may have a
considerable protective effect against metastasis or
advanced disease status in patients with PCa. This effect is
not associated with a biologically less aggressive (low
grade) tumor, but may be due to the modification of can-
cer progression and metastasis through the host's bone
metabolism. In order to clarify the role of OPG in the pro-
gression of PCa, further molecular studies are warranted.
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